

Accelerate life-changing treatments with LifeArc and iiCON

The Infection Innovation Consortium: iiCON is supporting organisations looking to humanise promising antibodies for infectious diseases – accelerating new treatments to patients.

Research groups and companies of all sizes can now access the world-leading antibody humanisation capability of self-funded, not-for-profit medical research organisation and charity LifeArc through iiCON, a global centre of infectious disease R&D.

Benefit from LifeArc’s comprehensive offering coupled with iiCON’s specialist infectious disease expertise, which supports every stage of the product development journey from discovery to patient impact.

The highly collaborative model is designed to support and de-risk innovation and bring new treatments to the market for patient benefit.

About iiCON:

iiCON is a world-leading collaborative infectious disease R&D programme led by Liverpool School of Tropical Medicine, with partners: LifeArc, Unilever, Evotec, Infex Therapeutics, University of Liverpool, and Liverpool University Hospitals NHS Foundation Trust.

With a global network of over 800 companies, iiCON’s c£200 million programme brings together industry, academia and clinicians to revolutionise the discovery, development, and deployment of new products to combat the growing threat posed by infectious diseases – saving lives through collaborative innovation.

About LifeArc’s humanisation programme:

LifeArc partners with organisations to humanise antibodies that could develop into life-changing therapeutics.

LifeArc has three decades of success working with strategic partners to humanise antibodies from different animal species to produce therapeutic candidates of diverse modalities such as IgG, VHH and VH-Fc.

LifeArc does not limit numbers of variants but rather uses high-throughput production and screening methods to assess hundreds of heavy/light chain combinations and a suite of biophysical assays to inform the choice of lead.

LifeArc’s collaborative and unique business model ensures humanised antibodies are optimised for clinical use.

COLLABORATE WITH US

Accelerate Innovation

Candidate antibodies are produced with optimal expression levels, binding and biophysical characteristics.

Through true collaboration

Progress is shared and samples provided for functional assessment throughout the project.

Where development is de-risked

LifeArc’s small royalty-based deal structure and extensive developability assessment helps to de-risk the process.

And fast-track life-changing treatments to patients

Become part of iiCON’s global network and access world-leading infectious disease expertise to propel your candidate’s progress to market.

Collaborate with us

Who can apply?

Research groups, companies, or organisations with promising antibodies for infectious diseases. We work with entities of all sizes across the globe with a strong commitment to supporting innovation and removing any barriers to entry.

What does the process involve?

- Initial discussion & review of acceptance criteria with iiCON's business development team. Support to draft & submit your application. Applications that meet the acceptance criteria will be taken forward to LifeArc.
- A truly collaborative model - progress is shared through regular updates throughout the project. Samples of antibodies are provided so partners can assess the engineered versions in functional assays at different stages.
- To aid the onward development of the humanised candidates, humanised antibodies are typically delivered in around six months.

What next?

- A comprehensive report covering all aspects of the work, key data and the biophysical characteristics of the antibodies is delivered. Partners have used this when submitting an IND (Investigational New Drug) filing or making patent applications.
- Partnering organisations benefit from iiCON's end-to-end support and expertise to take their candidate forward, with specialist commercial guidance alongside world-leading technical capability.



LIFEARC HAS OVER 30 YEARS' EXPERIENCE HUMANISING & OPTIMISING ANTIBODIES

94

antibodies humanised



51

companies served worldwide



98%

success rate



5

drugs on the market



Keytruda®
for cancer



Tysabri®
for multiple sclerosis



Entyvio®
for ulcerative colitis



Actemra®
for rheumatoid arthritis



Leqembi®
for Alzheimer's

SUCCESS IN NUMBERS

12

antibodies in the discovery phase



7

mAbs in pre-clinical development pipelines



8

mAbs in clinical pipelines



4

mAbs in clinical trials



1

programme entered phase II within two years completing humanisation



For more information, please contact:

Dr Elizabeth Crawford | Senior Business Development Manager, iiCON

✉ elizabeth.crawford@lstmed.ac.uk

